PharmSource – Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition

2017-07-12
Price :
Published : Jul-2017
No. of Pages : 29

PharmSource – Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition

Summary

Contract Dose Manufacturing universe, for purposes of this report, includes companies that actively promote themselves as contract manufacturers (CMOs) that produce a client’s formulation for pharmaceuticals supplied to the highly-regulated markets in North America, Europe and Japan. Contract dose manufacturing universe includes 282 companies headquar¬tered primarily in North America, Europe, Japan and India. One hundred and eighty-one companies (64%) pursue contract manufacturing as their primary business, while the remainder (36%) contract manufacture in facilities where they produce their own products.

Size of the dose CMO market in 2016 was $19.3 billion, a 4.0% increase from 2015. Organic growth, i.e., without the impact of acquisitions of facili¬ties from bio/ pharmaceutical companies, was 3.2%. Industry growth was also negatively impacted by facility remediation at Ferentino (Patheon) and Beinheim (Catalent). Standard dose products including solid dose, semisolid and non-injectable liquids, accounted for 51% of the market in 2016. Injectables accounted for 28% and specialty dose forms, including softgels, transdermal and blow-fill-seal, accounted for 21%.

From 2010-2014 the CMO sector grew at twice the rate of the bio/pharmaceu¬tical sector in mature markets including North America, Europe and Japan. Industry analysts expect that annual growth of the mature bio/pharmaceutical sector will be in the 2.5-3.5% range through 2019. PharmSource expects the CMO industry growth to continue to slow relative to overall industry growth despite the significant increase in New Active Substances launched from 2014 onwards. We see this primarily as a consequence of a decline in unit volume per product, while outsourcing pro¬pensity has remained stable for a decade.

The report “PharmSource – Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition” provides an important expert quantitative analysis on the contract dose manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm. Moreover, this report includes an Executive Summary and chapters on Industry Size and Structure, Industry Size and Growth, CMO Market Shares and concludes with a chapter on The Outlook for the Dose CMO Industry, which provides further analysis and assesses the report’s implications for the dose CMO industry. In addition, it includes an appendix on methodology.

Scope

– This report characterizes the contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size and market shares of the top CMOs, and provides PharmSource’s expert outlook for the industry.
– The contract dose manufacturing universe, for purposes of this report, includes companies that actively promote themselves as contract manufacturers (CMOs) that produce a client’s formulations for pharmaceuticals supplied to the highly regulated markets in North America, Europe and Japan.
– The report defines the contract dose manufacturing universe as including 282 companies headquartered primarily in North America, Europe, Japan and India.

Reasons to buy

The expertise and skilled analysis in this 29-page report gives important insight you won’t find in any other source. This report is required reading for –
– CMO executives and strategic decision-makers: you’ll find this report an indispensable resource for understanding the industry and a critical input for strategic planning efforts.
– Sourcing and procurement executives in bio/pharmaceutical companies: you’ll find the report a critical resource for understanding crucial components of the supply base that will provide insights for supplier selection and management.
– Private equity investors: you’ll get a deeper understanding of the market and important insight for identifying potential investment targets.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Pharmaceutical Gelatin Market by Source (Porcine, Bovine Skin, Bovine Bone, Fish, Poultry), Application (Hard Capsule, Soft Capsule, Tablet, Absorbable Hemostat), Function (Stabilizing, Thickening, Gelling), Region – Global Forecast to 2025

“The global pharmaceutical gelatin market is projected to grow at a CAGR of 5.3%.” The global pharmaceutical gelatin market is projected to reach USD 1.2 billion by 2025 from USD 1.0 billion in 2020, at a CAGR of 5.3% during the forecast period. Growth in this market is driven by the advantages of pharmaceutical gelatin such as utility and versatility in medical and biomedical applications, unique functional properties, natural source of origin, and the increasing demand for pharmaceutical applications such as hard capsules and soft gel capsules. However, factors such as cultural restrictions in consumption of porcine or bovine-derived gelatin, and rising prices of raw material are expected to restrain the growth of this market to a certain extent during the forecast period. “T......
$5650

Active Pharmaceutical Ingredient (API) Market by type (Innovative, generic), manufacturer (captive, merchant), synthesis (synthetic, biotech), by product (vaccines, Hormones), drug (OTC, Rx), application (Diabetes, oncology, CVD) – Global Forecast to 2025

““Increasing incidence of chronic diseases and technological advancements in API manufacturing,is expected to drive the overall growth of the global APIs market” The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period. Growth in the active pharmaceutical ingredients market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombin......
$4950

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – August 2020

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - August 2020 Summary GlobalData's "Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - August 2020" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies.......
$1000

External Remote Patient Monitoring Devices – Medical Devices Pipeline Assessment, 2020

External Remote Patient Monitoring Devices - Medical Devices Pipeline Assessment, 2020 Summary GlobalData's Medical Devices sector report, "External Remote Patient Monitoring Devices - Medical Devices Pipeline Assessment, 2020 " provides comprehensive information about the External Remote Patient Monitoring Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. External remote patient monitoring devices retrieves the data from the external measurement device (like glucose meters, blood pressure monitors. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type. Scope - Extensive coverage......
$4000

Vital Sign Monitors – Medical Devices Pipeline Assessment, 2020

Vital Sign Monitors - Medical Devices Pipeline Assessment, 2020 Summary GlobalData's Medical Devices sector report, "Vital Sign Monitors - Medical Devices Pipeline Assessment, 2020 " provides comprehensive information about the Vital Sign Monitors pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Vital sign monitors are used to measure and record the basic vital signs such as pulse rate, temperature and respiratory rate of an individual. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type. Scope - Extensive coverage of the Vital Sign Monitors under development - The report reviews det......
$4000

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Drug Sales Forecast, Q2 2020

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Drug Sales Forecast, Q2 2020 Summary This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Since the last edition of this report the number of COVID-19 therapies and vaccines with forecasts have increased dramatically. This report features the 14 most prominent drugs indicated for COVID-19 which have analyst consensus forecasts available. Scope This report is required reading for - - Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in - Companies that are interested in entering the COVID-19 disea......
$495

Crohn’s Disease – Global Drug Forecast and Market Analysis to 2029

Crohn's Disease - Global Drug Forecast and Market Analysis to 2029 Summary Crohn's disease (CD) is a form of inflammatory bowel disease (IBD), which is composed of two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area; however, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission. The CD market has historically been reliant on anti-tumor necrosis factor (anti-TNF) therapies that have been available for over a decade bu......
$10995

Coronavirus Disease (COVID-19) Implications on Health Insurance – August 2020

Coronavirus Disease (COVID-19) Implications on Health Insurance - August 2020 Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. The virus is also having a growing impact on the global economy including the health insurance industry. This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis. Key Highlights - Changes to certain telemedicine regulations are likely to be made permanent: The announcement of an E......
$495

Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions, Liquids, Solids, Transdermal Products), Route (Dermal, Rectal, Vaginal), Patient Care Setting (Homecare, Hospital, Burn Center) COVID-19 Impact – Global Forecast to 2025

The topical drug delivery market is expected to grow at a CAGR of 6.4% in the forecast period. The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period. The growth of this market is majorly driven by the high prevalence of skin and soft tissue infections, the increasing prevalence of eye diseases, and burns.However, the presence of alternative drug delivery modes such as oral and injectable routes is expected to restrain the growth of this market during the forecast period. Based on product, the semi-solid formulations segment holds the largest market share during the forecast period. Based on product, the topical drug delivery market is segmented into semi-solid formulations, liqui......
$4950

Cleanroom Technologies Market by Product (HVAC, HEPA Filters, Apparel, Vacuum Systems, Gloves, Disinfectants), Construction (Drywall, Hardwall, Softwall), End User (Pharmaceutical, Biotechnology, Hospitals) – COVID-19 Impact – Global Forecast to 2025

The cleanroom technologies market is expected to grow at a CAGR of 7.2 % in the forecast period. The cleanroom technologies market is projected to reach USD 7.3 billion by 2025 from USD 5.1 billion in 2020, at a CAGR of 7.2% during the forecast period. The growth of this market is majorly driven by the stringent regulatory framework, growth of the biologics sector, rising demand for sterilized pharmaceutical formulations, increasing demand for medical devices, and technological advancements in cleanroom technology. Also, the increasing demand in developing economies and the growing focus on energy-efficient cleanrooms are expected to offer significant opportunities for market growth in the coming years. However, the high operational cost associated with the cleanrooms is expected to res......
$4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy